Clene to Provide CNM-Au8® ALS Program Update
Rhea-AI Summary
Clene (Nasdaq: CLNN) will host a CNM-Au8 ALS program update webcast and investor call on December 3, 2025 at 8:30 a.m. ET.
Presenters include Rob Etherington (CEO and President), Dr. Ben Greenberg (Head of Medical), Michael Hotchkin (Chief Development Officer) and a key opinion leader. The live webcast link and dial‑in numbers are provided for U.S. and international participants, and an archived webcast will be available on the company website approximately two hours after the event.
Positive
- None.
Negative
- None.
Webcast set for 8:30 a.m. ET on December 3rd
SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced it plans provide an update on its CNM-Au8 program in ALS, and to host an investor call and webcast at 8:30 am ET on Wednesday, December 3, 2025. The webcast is accessible via the link below or the Investors section of the Company’s website located here.
Webcast Information:
Title: CNM-Au8 ALS Program Update
Presenters: Rob Etherington, CEO and President, Dr. Ben Greenberg, Head of Medical, Michael Hotchkin, Chief Development Officer and a KOL
Date: December 3, 2025
Start Time: 8:30 a.m. ET
Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1744985&tp_key=9fb9583d33
Dial number: 1-877-407-0779 (US) or 1-201-389-0914 (international), Conference ID#13757380
The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc.), is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
About CNM-Au8®
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc.
Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856
FAQ
When is Clene (CLNN) holding the CNM-Au8 ALS program update webcast?
Who are the presenters on the Clene (CLNN) CNM-Au8 ALS investor call on December 3, 2025?
How can investors access the Clene (CLNN) CNM-Au8 ALS webcast on December 3, 2025?
Will Clene (CLNN) make the CNM-Au8 ALS webcast available after the live event?
What topic will Clene (CLNN) cover in the December 3, 2025 webcast?
